News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Leading Experts In The Field Of AML Treatment And Bone Marrow Transplant To Discuss Available Treatment Options And Potential New Opportunities Including Actinium Pharmaceuticals, Inc. (ATNM.OB)’s Iomab™-B At NY Biotechnology Industry Organization (BIO) Conference


5/13/2014 7:26:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced participation in an upcoming panel discussion highlighting the potential role of Actinium’s products in the treatment of older refractory/relapsed acute myeloid leukemia (AML) patients.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES